FAQs

Show all

Geron common stock trades on the Nasdaq Global Select Market under the ticker symbol “GERN”.
Geron was incorporated in Delaware in November 1990.
Geron is located in Menlo Park, which is in the San Francisco Bay Area. The address of our corporate offices is 149 Commonwealth Drive, Menlo Park, CA 94025. The main telephone number is +1-650-473-7700.
December 31st. Geron is on a calendar year-end schedule.
Ernst & Young LLP
275 Shoreline Drive, Suite 600
Redwood City, CA 94065
The company has not paid any cash dividends to its stockholders since its inception and does not plan to pay cash dividends in the foreseeable future.
No. Geron has not paid and does not intend to pay cash dividends in the foreseeable future and therefore does not have a dividend reinvestment program.
No. Geron does not have a direct stock purchase program. You will need to contact your broker or purchase shares through an online stock transaction service.
Computershare
250 Royall Street
Canton, MA 02021
Tel: 1-800-962-4284
Website: www.computershare.com/investor
Shareholder online inquiries: www-us.computershare.com/investor/Contact
If your shares are held in your name, you may contact Computershare Trust Company as indicated above. If your shares are held in Street name, you must contact your broker to update your address.
Electronic copies of Geron’s Annual Report on Form 10-K are available through the SEC Filings page. Please email investor@geron.com to request that an Annual Report be mailed to you.
We do not maintain a postal mailing list for materials. However, if you would like to join our email distribution list for press releases, please send your name and email address to investor@geron.com.
Imetelstat is partnered with Janssen Biotech, Inc. under an exclusive worldwide collaboration and license agreement. Please visit our Partners page for more information.
Geron is no longer funding development of the stem cell programs. On October 1, 2013, Geron closed the transaction to divest its human embryonic stem cell assets and autologous cellular immunotherapy program to Asterias Biotherapeutics, Inc. In connection with the divestiture, Geron received 6,537,779 shares of Asterias Series A common stock. On August 15, 2014, Geron completed the distribution of the Asterias Series A common stock to eligible Geron stockholders. Click here for more information.
You may contact Investor Relations via email at investor@geron.com or by phone at +1-650-473-7765.
Please contact Media Relations via email at media@geron.com or at 650-473-7765.